Horizon Therapeutics down as SLE drug fails mid-stage study

Horizon Therapeutics

21/07/2023 22:40

** Shares of biotechnology company Horizon Therapeutics
 HZNP.O  down 1.12% at $100.05 after the bell
    ** Company reports its mid-stage trial evaluating daxdilimab
for the treatment of SLE did not meet main goal
    ** "We will continue to work with investigators to assess
these data to determine next steps for our SLE clinical program"
- HZNP
    ** HZNP shares down 11.09%, as of last close 

 (Reporting by Pritam Biswas in Bengaluru)
 ((Pritam.Biswas@thomsonreuters.com))